Intelligence · Clinical Development
Pipeline search results
Programs matching “pembrolizumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 75 pipeline programs matching "pembrolizumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
pembrolizumab
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
2 trials -
pembrolizumab/vibostolimab
Merck KGaA, Darmstadt, Germany
Carcinoma, Non-Small-Cell Lung
1 trial -
2025-SR-813
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
APR-246 (eprenetapopt) + Pembrolizumab
Aprea Therapeutics
Bladder Cancer
1 trial -
Ataluren + Pembrolizumab
PTC THERAPEUTICS, INC.
Colorectal Cancer
1 trial -
BXCL701 plus Pembrolizumab
BioXcel Therapeutics
Prostate Cancer
1 trial -
Drug: Pembrolizumab
Hospital Authority, Hong Kong
Clear-cell Metastatic Renal Cell Carcinoma
1 trial -
GEN1042 DP, PEMBROLIZUMAB
Genmab A/S
Metastatic Solid Malignant tumors
1 trial -
IO102-IO103 in combination with pembrolizumab
IO Biotech
Lung Cancer Non Small Cell
1 trial -
NEO-201 in combination with pembrolizumab
Chongqing Precision Biotech Co., Ltd
Non Small Cell Lung Cancer
1 trial -
PEMBROLIZUMAB
Pari Pharma GmbH
Kaposi's sarcoma
1 trial -
PEMBROLIZUMAB, PM54
Lacuna Pharma Pty Ltd
Advanced malignancies
1 trial -
Pembrolizumab
Syndax Pharmaceuticals
Metastatic Uveal Melanoma
1 trial -
Pembrolizumab
Incyte
Lung Cancer
2 trials -
Pembrolizumab
Genmab A/S
Advanced Endometrial Cancer
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Advanced Non-Small Cell Lung Cancer
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Melanoma
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Castration-resistant Prostate Cancer
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Metastatic Small Intestinal Adenocarcinoma
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Pancreatic Cancer
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Triple Negative Breast Cancer
1 trial -
Pembrolizumab
TG THERAPEUTICS, INC.
Hodgkin's Lymphoma
1 trial -
Pembrolizumab
Syndax Pharmaceuticals
Bladder Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.